Canadian Body Calls For Investment In Domestic Production
CGPA Blueprint Also Urges Enhanced International Role And Local Stockpiling
Executive Summary
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.
You may also be interested in...
Canadian Budget Does Not Go Far Enough
While a promised investment in the life sciences sector included in the latest Canadian federal budget has been welcomed by the local off-patent industry, it says a “more comprehensive approach” is needed.
Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.